Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tilarginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 known ✓ | P35228 | 8/20 | 0.50 |
| ▸ | NOS1 known ✓ | P29475 | 7/20 | 0.50 |
| ▸ | NOS3 known ✓ | P29474 | 4/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 5/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tilarginine SCHEMBL29377396 | 1.00 | DDAH1 (0.56) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| Tilarginine SCHEMBL29393308 | 1.00 | DDAH1 (0.56) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| Tilarginine SCHEMBL10198569 | 0.97 | DDAH1 (0.58) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| Tilarginine SCHEMBL7450191 | 0.97 | DDAH1 (0.58) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| Tilarginine SCHEMBL1736031 | 0.97 | DDAH1 (0.58) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| Tilarginine SCHEMBL349879 | 0.97 | DDAH1 (0.58) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| Tilarginine SCHEMBL31106009 | 0.95 | DDAH1 (0.57) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| Tilarginine SCHEMBL29711436 | 0.95 | DDAH1 (0.57) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| SCHEMBL24691538 | 0.92 | DDAH1 (0.54) | DDAH1NOS2NOS1NOS3CYP2C19 | |
| SCHEMBL12825469 | 0.87 | DDAH1 (0.44) | DDAH1NOS2NOS1NOS3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357850-B2 | Methods for treating breast cancer using INOS-inhibitory compositions | THE METHODIST HOSPITAL (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200306371-A1 | METHODS FOR TREATING BREAST CANCER USING INOS-INHIBITORY COMPOSITIONS | THE METHODIST HOSPITAL | 2020-10-01 | — | — | US | disclosed |
| US-10420838-B2 | Methods for treating cancer using iNOS-inhibitory compositions | THE METHODIST HOSPITAL (US) | 2019-09-24 | — | — | US | disclosed |
| EP-2349242-B1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS INC (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20170224814-A1 | METHODS FOR TREATING CANCER USING INOS-INHIBITORY COMPOSITIONS | THE METHODIST HOSPITAL | 2017-08-10 | — | — | US | disclosed |
| US-20170020835-A1 | INOS-INHIBITORY COMPOSITIONS AND THEIR USE AS BREAST CANCER THERAPEUTICS | THE METHODIST HOSPITAL | 2017-01-26 | — | — | US | disclosed |
| US-20160271153-A1 | Novel Methods For The Treatment Of Cardiac Arrhythmias | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2016-09-22 | — | — | US | disclosed |
| US-8722739-B2 | Amino acid salts of prostaglandins | NOVAER HOLDINGS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140031423-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8623918-B2 | Amino acid salts of prostaglandins | NOVAER HOLDINGS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8470882-B2 | — | — | 2013-06-25 | — | — | US | disclosed |
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105775-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | NOVAER HOLDINGS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC (CA) | 2009-09-10 | — | — | US | disclosed |
| EP-1978930-A2 | SUTURES AND ANTI-SCARRING AGENTS | Angiotech Pharmaceuticals, Inc. (CA) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007089878-A2 | SUTURES AND ANTI-SCARRING AGENTS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006121522-A2 | IMPLANTABLE SENSORS AND PUMPS, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121518-A2 | ELECTRICAL DEVICES, ANTI-SCARRING AGENTS, AND THERAPEUTIC COMPOSITIONS | ANGIOTECH INTERNATIONAL AG (CH) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105771-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | NOS2 57/4885NOS1 166/4885NOS3 98/4885 |
| US-20100105775-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | NOS2 57/4885NOS1 166/4885NOS3 98/4885 |
| US-20140031423-A1 | AMINO ACID SALTS OF PROSTAGLANDINS | PTGIS, PTGES, PTGIR | NOS2 57/4885NOS1 166/4885NOS3 98/4885 |
| US-20090226500-A1 | SUTURES AND ANTI-SCARRING AGENTS | COL1A1, COL2A1, COL14A1 | NOS2 1735/4885NOS1 1460/4885NOS3 1752/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | NOS2 507/4885NOS1 357/4885NOS3 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.